April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Increased Scotopic and Photopic A-Wave Amplitude Electroretinogram Responses After Intravitreal Bevacizumab Injection in Patients With Neovascular Age-Related Macular Degeneration
Author Affiliations & Notes
  • Y. Rotenstreich
    Goldscheleger Eye Institute, Tel-Aviv University, Tel Hashomer, Israel
  • A. Solomon
    Goldscheleger Eye Institute, Tel-Aviv University, Tel Hashomer, Israel
  • A. Skaat
    Goldscheleger Eye Institute, Tel-Aviv University, Tel Hashomer, Israel
  • I. Moroz
    Goldscheleger Eye Institute, Tel-Aviv University, Tel Hashomer, Israel
  • Footnotes
    Commercial Relationships  Y. Rotenstreich, None; A. Solomon, None; A. Skaat, None; I. Moroz, None.
  • Footnotes
    Support  Vladimir Shriber Tel-Aviv Univirsity Fund
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 1885. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Rotenstreich, A. Solomon, A. Skaat, I. Moroz; Increased Scotopic and Photopic A-Wave Amplitude Electroretinogram Responses After Intravitreal Bevacizumab Injection in Patients With Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1885.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess the effect of Bevacizumab (Avastin®), a vascular endothelial growth factor inhibitor on the retinal function by full-field electroretinogram (ERG) in patients with choroidal neovascular Age-related Macular Degeneration (AMD).

Methods: : Masked, controlled study, included 12 patients with choroidal neovascular AMD, mean age 72 ± 11.5 years, (5 men and 7 women) . The patients were injected with bevacizumab 1.25 mg/0.05 ml (Genentech, San Francisco, CA) unilaterally into the vitreous cavity as part of the standard management. Prior to bevacizumab injection and one month post-injection, full-field ERG (ISCEV; LKC Technologies, Gaithersburg, MD) scans were obtained from both eyes of each patient while the other eye was used as a control group. Scotopic responses were recorded under four incremental light intensities stimuli (0.099 cd-s/m2, 2.44 cd-s/m2, 23.5 cd-s/m2 and 252 cd-s/m2). The photopic responses were evoked by two incremental light intensities (2.44 cd-s/m2 and 7.8 cd-s/m2). The differences before and after treatment for the waves amplitude were calculated and the data were analyzed using repeated measure ANOVA model.

Results: : The average differences for the incremental light intestacies of the scotopic a-wave amplitude in the injected eyes was 15.92 microvolt, compare to 1.33 microvolt in the controlled eyes (P=0.057, ANOVA). The average differences of the photopic a-wave amplitude were 4.97 microvolt in the injected eye and -1.06 microvolt in the control eyes (P=0.01, ANOVA). The average differences of the scotopic b-wave amplitude in the injected and controlled eyes were 13.56 microvolt and 4.11 microvolt respectively (P=0.23, ANOVA). The average differences for the photopic b-wave amplitude in the injected eyes was 5.07 microvolt and -2.70 microvolt in the controlled eyes (P=0.048, ANOVA).

Conclusions: : Intravitreal injection of bevacizumab improved rods and cones function in neovascular AMD patients. No significant measurable photoreceptor toxicity was observed by the ERG tests.

Clinical Trial: : www.clinicaltrials.gov NCT00478530

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • electroretinography: clinical 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×